Chemoinformaics analysis of 4,21-Dehydrocorynantheine aldehyde
| Molecular Weight | 351.426 | nRot | 3 |
| Heavy Atom Molecular Weight | 328.242 | nRig | 23 |
| Exact Molecular Weight | 351.17 | nRing | 4 |
| Solubility: LogS | -3.834 | nHRing | 3 |
| Solubility: LogP | 2.761 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 49 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 26 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 23 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 21 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 9 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 10 |
| nHA | 3 | APOL | 55.0122 |
| nHD | 2 | BPOL | 27.9578 |
| QED | 0.303 |
| Synth | 4.765 |
| Natural Product Likeliness | 1.21 |
| NR-PPAR-gamma | 0.113 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.346 |
| HIA | 0.087 |
| CACO-2 | -4.777 |
| MDCK | 0.0000235 |
| BBB | 0.221 |
| PPB | 0.647534 |
| VDSS | 1.727 |
| FU | 0.239423 |
| CYP1A2-inh | 0.162 |
| CYP1A2-sub | 0.813 |
| CYP2c19-inh | 0.061 |
| CYP2c19-sub | 0.4 |
| CYP2c9-inh | 0.024 |
| CYP2c9-sub | 0.137 |
| CYP2d6-inh | 0.021 |
| CYP2d6-sub | 0.495 |
| CYP3a4-inh | 0.928 |
| CYP3a4-sub | 0.505 |
| CL | 2.619 |
| T12 | 0.356 |
| hERG | 0.064 |
| Ames | 0.018 |
| ROA | 0.466 |
| SkinSen | 0.75 |
| Carcinogencity | 0.126 |
| EI | 0.017 |
| Respiratory | 0.943 |
| NR-Aromatase | 0.119 |
| Antiviral | Yes |
| Prediction | 0.584074 |